Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Designing of inhibitors against drug tolerant Mycobacterium tuberculosis (H37Rv).

Singla D, Tewari R, Kumar A, Raghava GP; Open Source Drug Discovery Consortium..

Chem Cent J. 2013 Mar 8;7(1):49. doi: 10.1186/1752-153X-7-49.

2.

DrugMint: a webserver for predicting and designing of drug-like molecules.

Dhanda SK, Singla D, Mondal AK, Raghava GP.

Biol Direct. 2013 Nov 5;8:28. doi: 10.1186/1745-6150-8-28.

3.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
5.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
6.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
7.

QSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forest.

Singh H, Singh S, Singla D, Agarwal SM, Raghava GP.

Biol Direct. 2015 Mar 25;10:10. doi: 10.1186/s13062-015-0046-9.

8.

Prediction of anticancer molecules using hybrid model developed on molecules screened against NCI-60 cancer cell lines.

Singh H, Kumar R, Singh S, Chaudhary K, Gautam A, Raghava GP.

BMC Cancer. 2016 Feb 9;16:77. doi: 10.1186/s12885-016-2082-y.

9.

A web server for predicting inhibitors against bacterial target GlmU protein.

Singla D, Anurag M, Dash D, Raghava GP.

BMC Pharmacol. 2011 Jul 6;11:5. doi: 10.1186/1471-2210-11-5.

10.
11.

CAPi: Computational Model for Apicoplast Inhibitors Prediction Against Plasmodium Parasite.

Dixit S, Singla D.

Curr Comput Aided Drug Des. 2017 Mar 1. doi: 10.2174/1573409913666170301121110. [Epub ahead of print]

PMID:
28260517
12.

Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.

Singh S, Roy KK, Khan SR, Kashyap VK, Sharma A, Jaiswal S, Sharma SK, Krishnan MY, Chaturvedi V, Lal J, Sinha S, Dasgupta A, Srivastava R, Saxena AK.

Bioorg Med Chem. 2015 Feb 15;23(4):742-52. doi: 10.1016/j.bmc.2014.12.060. Epub 2015 Jan 2. Erratum in: Bioorg Med Chem. 2015 Jul 1;23(13):3871. Gupta, Arnab D [corrected to Dasgupta, Arunava].

PMID:
25614114
13.

Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.

Uc-Cachón AH, Borges-Argáez R, Said-Fernández S, Vargas-Villarreal J, González-Salazar F, Méndez-González M, Cáceres-Farfán M, Molina-Salinas GM.

Pulm Pharmacol Ther. 2014 Feb;27(1):114-20. doi: 10.1016/j.pupt.2013.08.001. Epub 2013 Aug 20.

PMID:
23968826
14.

[Prospects for development of new antituberculous drugs].

Tomioka H.

Kekkaku. 2002 Aug;77(8):573-84. Japanese.

PMID:
12235850
15.

Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors.

Xia Z, Yan A.

Mol Divers. 2017 May 8. doi: 10.1007/s11030-017-9743-x. [Epub ahead of print]

PMID:
28484935
16.

Key targets and relevant inhibitors for the drug discovery of tuberculosis.

Xiong X, Xu Z, Yang Z, Liu Y, Wang D, Dong M, Parker EJ, Zhu W.

Curr Drug Targets. 2013 Jun 1;14(6):676-99. Review.

PMID:
23547780
17.

A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.

Shen H, Wang F, Zhang Y, Huang Q, Xu S, Hu H, Yue J, Wang H.

FEBS J. 2009 Jan;276(1):144-54. doi: 10.1111/j.1742-4658.2008.06763.x. Epub 2008 Nov 20.

18.

Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.

Liu Y, Zhou S, Deng Q, Li X, Meng J, Guan Y, Li C, Xiao C.

Tuberculosis (Edinb). 2016 Mar;97:38-46. doi: 10.1016/j.tube.2015.12.003. Epub 2016 Jan 6.

PMID:
26980494
19.

Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs.

Khare G, Kar R, Tyagi AK.

PLoS One. 2011;6(7):e22441. doi: 10.1371/journal.pone.0022441. Epub 2011 Jul 26.

20.

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M.

PLoS Med. 2006 Nov;3(11):e466.

Supplemental Content

Support Center